Cite
MLA Citation
A Buisson et al.. “P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study.” Journal of Crohn's and colitis, vol. 16, n.d., pp. i393–i394. http://access.bl.uk/ark:/81055/vdc_100150514768.0x000030